These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 29132396)

  • 1. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
    Cheng X; Zhang L; Chen Y; Qing C
    J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy in ovarian cancer.
    Giannopoulou L; Lianidou ES
    Adv Clin Chem; 2020; 97():13-71. PubMed ID: 32448432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
    Giannopoulou L; Kasimir-Bauer S; Lianidou ES
    Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.
    Esposito A; Criscitiello C; Trapani D; Curigliano G
    Curr Oncol Rep; 2017 Jan; 19(1):1. PubMed ID: 28110461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells as a "real-time liquid biopsy": Recent advances and the application in ovarian cancer.
    Jou HJ; Ling PY; Hsu HT
    Taiwan J Obstet Gynecol; 2022 Jan; 61(1):34-39. PubMed ID: 35181043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.
    Esposito A; Bardelli A; Criscitiello C; Colombo N; Gelao L; Fumagalli L; Minchella I; Locatelli M; Goldhirsch A; Curigliano G
    Cancer Treat Rev; 2014 Jun; 40(5):648-55. PubMed ID: 24184333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical utility of liquid biopsies in ovarian cancer.
    Zhu JW; Charkhchi P; Akbari MR
    Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
    Balla A; Bhak J; Biró O
    Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
    Chebouti I; Kuhlmann JD; Buderath P; Weber S; Wimberger P; Bokeloh Y; Hauch S; Kimmig R; Kasimir-Bauer S
    Oncotarget; 2017 Apr; 8(15):24303-24313. PubMed ID: 28388557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
    Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
    Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer.
    Nordgård O; Tjensvoll K; Gilje B; Søreide K
    Br J Surg; 2018 Jan; 105(2):e110-e120. PubMed ID: 29341153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.
    Giannopoulou L; Zavridou M; Kasimir-Bauer S; Lianidou ES
    Transl Res; 2019 Mar; 205():77-91. PubMed ID: 30391474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of liquid biopsies in gastrointestinal cancer.
    Wu C; Zhang J; Li H; Xu W; Zhang X
    Clin Biochem; 2020 Oct; 84():1-12. PubMed ID: 32540214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
    von Bubnoff N
    Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
    Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
    Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy for ovarian cancer using circulating tumor cells: Recent advances on the path to precision medicine.
    Yang J; Cheng S; Zhang N; Jin Y; Wang Y
    Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188660. PubMed ID: 34800546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
    He J; Tan W; Ma J
    Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.